TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

被引：17

作者：

Burris, Howard A. ^{[1
,2
]}

Patel, Manish R. ^{[1
,3
]}

Brander, Danielle M. ^{[4
]}

O'Connor, Owen A. ^{[5
]}

Deng, Changchun ^{[5
]}

Fenske, Timothy S. ^{[6
]}

Gutierrez, Martin ^{[7
]}

Jones, Suzanne ^{[1
]}

Kuhn, John ^{[8
]}

Miskin, Hari P. ^{[9
]}

Sportelli, Peter ^{[9
]}

Vakkalanka, Swaroop ^{[10
]}

Flinn, Ian ^{[1
,11
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Tennessee Oncol PPLC, Nashville, TN USA

[3] Florida Canc Specialists, Ft Myers, FL USA

[4] Duke Univ, Med Ctr, Durham, NC USA

[5] Columbia Univ, Med Ctr, New York, NY USA

[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[7] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[8] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

[9] TG Therapeut Inc, New York, NY USA

[10] Rhizen Pharmaceut SA, La Chaux De Fonds, Switzerland

[11] Tennessee Oncol PLLC, Nashville, TN USA

来源：

关键词：

D O I：

10.1182/blood.V124.21.1984.1984

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3